<code id='CD761B1D64'></code><style id='CD761B1D64'></style>
    • <acronym id='CD761B1D64'></acronym>
      <center id='CD761B1D64'><center id='CD761B1D64'><tfoot id='CD761B1D64'></tfoot></center><abbr id='CD761B1D64'><dir id='CD761B1D64'><tfoot id='CD761B1D64'></tfoot><noframes id='CD761B1D64'>

    • <optgroup id='CD761B1D64'><strike id='CD761B1D64'><sup id='CD761B1D64'></sup></strike><code id='CD761B1D64'></code></optgroup>
        1. <b id='CD761B1D64'><label id='CD761B1D64'><select id='CD761B1D64'><dt id='CD761B1D64'><span id='CD761B1D64'></span></dt></select></label></b><u id='CD761B1D64'></u>
          <i id='CD761B1D64'><strike id='CD761B1D64'><tt id='CD761B1D64'><pre id='CD761B1D64'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          hotspot

          author:leisure time    - browse:68
          Cholesterol
          APStock

          Verve Therapeutics said Sunday that the first 10 people to receive a one-time treatment powered by a form of CRISPR called base editing showed reductions in bad cholesterol levels — study results that are preliminary but signal the potential for gene-editing treatments to benefit people with an inherited type of cardiovascular disease.

          Three of the study participants treated with potentially therapeutic doses of the Verve drug, called VERVE-101, showed  reductions in LDL-C levels of 39%, 48%, and 55%, respectively. The latter patient’s decline in so-called “bad” cholesterol was maintained for six months.

          advertisement

          The Verve-101 study results were presented at the American Heart Association conference and are the first data in patients from a therapy that uses base editing to change individual letters of DNA. Verve licensed the base-editing technology from Beam Therapeutics.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge